384 related articles for article (PubMed ID: 18025856)
1. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
[TBL] [Abstract][Full Text] [Related]
2. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
Chang SL; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
[TBL] [Abstract][Full Text] [Related]
3. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
5. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
6. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
Shen S; Lepor H; Yaffee R; Taneja SS
J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
[TBL] [Abstract][Full Text] [Related]
7. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
8. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group.
Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2009 Dec; 104(11):1604-9. PubMed ID: 19549124
[TBL] [Abstract][Full Text] [Related]
9. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
10. Efficiency of ultrasensitive prostate-specific antigen assay in diagnosing biochemical failure after radical prostatectomy.
Shimizu F; Tanaka S; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Jun; 37(6):446-51. PubMed ID: 17656483
[TBL] [Abstract][Full Text] [Related]
11. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
Malik RD; Goldberg JD; Hochman T; Lepor H
Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
[TBL] [Abstract][Full Text] [Related]
12. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.
Nakamura M; Hasumi H; Miyoshi Y; Sugiura S; Fujinami K; Yao M; Kubota Y; Uemura H
Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609
[TBL] [Abstract][Full Text] [Related]
16. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
18. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
Pruthi RS; Johnstone I; Tu IP; Stamey TA
Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
[TBL] [Abstract][Full Text] [Related]
20. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
J Clin Oncol; 2007 May; 25(13):1765-71. PubMed ID: 17470867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
